Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype

Paquet, Eric R., Hallett, Michael T.·2015·JNCI: Journal of the National Cancer Institute

Abstract

BACKGROUND: Massively parallel gene expression profiling has provided a more objective, molecular-level characterization of breast cancer subtypes. Several bioinformatics tools are available to infer patient subtype from a gene expression profile including the well-studied PAM50. The specific algorithmic methods used in these tools require access to a broad patient dataset. The choice of subtype for an individual is determined relative to all other patients across the panel, making subtypes heavily dependent on the composition of the dataset. Our aim was to develop a bioinformatics approach assigning absolute breast cancer subtypes, independent of dataset composition. METHODS: Using a dataset of 4924 breast cancer patients, we defined a new bioinformatics approach: Absolute Intrinsic Molecular Subtyping (AIMS) that assigns subtype from a gene expression profile for an individual sample without the need for a large, diverse, and normalized dataset. We evaluated the agreement of AIMS with PAM50 and compared subtype assignment and prognostic value of the subtypes. We assessed AIMS' robustness using a benchmark set of tests including subtype reproducibility between technologies, gene removal, and normal gene expression contamination, and compared it with PAM50. All statistical tests, except where noted, were two-sided. RESULTS: AIMS vastly agreed with PAM50, with 76% and 77% agreement for cross validation and the test set, respectively, and the prognostic capacity of the intrinsic subtypes was preserved. AIMS is fully stable, and its absolute nature enables its use on a wide range of datasets and technologies, including RNA-seq. CONCLUSIONS: The instability of a breast cancer subtyping scheme like PAM50 could have important consequences in clinical management of patients. AIMS is a fully stable and robust subtyping scheme that recapitulates PAM50.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/dju357

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 35

  1. Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 · DOI · Paper page
  2. Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, 10869, 10.1073/pnas.191367098 · DOI · Paper page
  3. Weigelt, 2010, The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade, J Pathol, 220, 263, 10.1002/path.2648 · DOI · Paper page
  4. Gruvberger, 2001, Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns, Cancer Res, 61, 5979
  5. Pusztai, 2003, Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors, Clin Cancer Res, 9, 2406
  6. Goldhirsch, 2011, Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann Oncol, 22, 1736, 10.1093/annonc/mdr304 · DOI · Paper page
  7. Harbeck, 2013, Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow, Cancer Treat Rev, 40, 434, 10.1016/j.ctrv.2013.09.014 · DOI
  8. Guedj, 2012, A refined molecular taxonomy of breast cancer, Oncogene, 31, 1196, 10.1038/onc.2011.301 · DOI · Paper page
  9. Lehmann, 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, 121, 2750, 10.1172/JCI45014 · DOI · Paper page
  10. Jonsson, 2010, Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics, Breast Cancer Res, 12, R42, 10.1186/bcr2596 · DOI · Paper page
  11. Lusa, 2007, Challenges in projecting clustering results across gene expression-profiling datasets, J Natl Cancer Inst, 99, 1715, 10.1093/jnci/djm216 · DOI
  12. Sorlie, 2010, The importance of gene-centring microarray data, Lancet Oncol, 11, 719, 10.1016/S1470-2045(10)70174-1 · DOI
  13. Weigelt, 2010, Breast cancer molecular profiling with single sample predictors: a retrospective analysis, Lancet Oncol, 11, 339, 10.1016/S1470-2045(10)70008-5 · DOI · Paper page
  14. Perou, 2010, Clinical implementation of the intrinsic subtypes of breast cancer, Lancet Oncol, 11, 718, 10.1016/S1470-2045(10)70176-5 · DOI
  15. Gautier, 2004, affy--analysis of Affymetrix GeneChip data at the probe level, Bioinformatics, 20, 307, 10.1093/bioinformatics/btg405 · DOI · Paper page
  16. Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 27, 1160, 10.1200/JCO.2008.18.1370 · DOI · Paper page
  17. Tofigh, 2014, The prognostic ease and difficulty of invasive breast carcinoma, Cell Reports, 9, 129, 10.1016/j.celrep.2014.08.073 · DOI
  18. Prat, 2014, Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study, Clin Cancer Res, 20, 511, 10.1158/1078-0432.CCR-13-0239 · DOI · Paper page
  19. Hu, 2006, The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics, 96, 10.1186/1471-2164-7-96 · DOI · Paper page
  20. Desmedt, 2008, Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes, Clin Cancer Res, 14, 5158, 10.1158/1078-0432.CCR-07-4756 · DOI · Paper page
  21. Wirapati, 2008, Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures, Breast Cancer Res, 10, R65, 10.1186/bcr2124 · DOI · Paper page
  22. Haibe-Kains, 2012, A three-gene model to robustly identify breast cancer molecular subtypes, J Natl Cancer Inst, 104, 311, 10.1093/jnci/djr545 · DOI · Paper page
  23. Tan, 2005, Simple decision rules for classifying human cancers from gene expression profiles, Bioinformatics, 21, 3896, 10.1093/bioinformatics/bti631 · DOI · Paper page
  24. Elloumi, 2011, Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples, BMC Med Genomics, 4, 54, 10.1186/1755-8794-4-54 · DOI
  25. Hoffman, 2010, CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses, Cancer Res, 70, 1459, 10.1158/0008-5472.CAN-09-3798 · DOI · Paper page
  26. Lee, 2011, Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women, J Clin Oncol, 29, 4373, 10.1200/JCO.2010.33.6446 · DOI
  27. Stead, 2009, Triple-negative breast cancers are increased in black women regardless of age or body mass index, Breast Cancer Res, 11, R18, 10.1186/bcr2242 · DOI · Paper page
  28. Cicatiello, 2010, Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs, Am J Pathol, 176, 2113, 10.2353/ajpath.2010.090837 · DOI · Paper page
  29. Wen, 2011, Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map, PLoS ONE, 6, e18278, 10.1371/journal.pone.0018278 · DOI
  30. Dowsett, 2013, Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, 31, 2783, 10.1200/JCO.2012.46.1558 · DOI · Paper page
  31. Lu, 2008, Predicting features of breast cancer with gene expression patterns, Breast Cancer Res Treat, 108, 191, 10.1007/s10549-007-9596-6 · DOI · Paper page
  32. Li, 2010, Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer, Nat Med, 16, 214, 10.1038/nm.2090 · DOI · Paper page
  33. Loi, 2007, Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade, J Clin Oncol, 25, 1239, 10.1200/JCO.2006.07.1522 · DOI · Paper page
  34. Miller, 2005, An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival, Proc Natl Acad Sci U S A, 102, 13550, 10.1073/pnas.0506230102 · DOI · Paper page
  35. Pawitan, 2005, Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts, Breast Cancer Res, 7, R953, 10.1186/bcr1325 · DOI · Paper page

Cited by

See all 186

Metadata

Authors
Paquet, E. R., & Hallett, M. T.
Venue
JNCI: Journal of the National Cancer Institute
Published
2014-12-04
Volume
107
Issue
1
Pages
357-357
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2157168213
Cited by
186
References
4
FWCI
2.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype. https://app.cochat.ai/papers/10.1093/jnci/dju357
The paper
Paquet, E. R., & Hallett, M. T. (2015). Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/dju357

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.